| Q65342401 | A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus |
| Q64638522 | A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealt |
| Q66081895 | A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment |
| Q63597356 | A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus |
| Q64396443 | A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function |
| Q100788366 | A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine |
| Q64376420 | A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus |
| Q64597916 | A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms |
| Q113889907 | A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times |
| Q113925355 | A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide |
| Q64222997 | A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam |
| Q63578280 | A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes |
| Q64140272 | A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects |
| Q64637674 | A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A |
| Q65369499 | A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes |
| Q63817289 | A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis |
| Q64805745 | A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM) |
| Q64657357 | A Pan Asian Trial Comparing Efficacy and Safety of NN5401 and Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q63843671 | A Pilot Study to Determine the Impact of Clopidogrel (Plavix®) on Bleeding Associated With Punch Biopsies in Healthy Volunteers |
| Q63819130 | A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India |
| Q64043661 | A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide |
| Q64631816 | A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Trea |
| Q64641924 | A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes |
| Q61894338 | A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes |
| Q64635492 | A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years |
| Q63840429 | A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease |
| Q63839980 | A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis |
| Q63404623 | A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea |
| Q64795657 | A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea. |
| Q113929202 | A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland |
| Q66061897 | A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes |
| Q113920654 | A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors |
| Q66062908 | A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity |
| Q113915010 | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) |
| Q113915008 | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) |
| Q113927231 | A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People |
| Q113933389 | A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause |
| Q113932679 | A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity |
| Q63597949 | A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus |
| Q105089513 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice |
| Q99529654 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice |
| Q113936180 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice |
| Q107189355 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Japan, as Part of Local Clinical Practice |
| Q113944955 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Mexico, as Part of Local Clinical Practice |
| Q113927609 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice |
| Q113893864 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Sweden, as Part of Local Clinical Practice |
| Q113889673 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice |
| Q105088759 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice |
| Q113911331 | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice |
| Q64802365 | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice |
| Q62025599 | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN) |
| Q64139943 | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND) |
| Q64150151 | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS) |
| Q63808543 | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK) |
| Q63587194 | A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine |
| Q113921998 | A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes |
| Q64150584 | A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A |
| Q113898176 | A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men |
| Q113939597 | A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice |
| Q113945770 | A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors |
| Q62811656 | A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity |
| Q113926143 | A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People |
| Q66067956 | A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day |
| Q63583322 | A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day |
| Q64150161 | A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine |
| Q62031676 | A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week |
| Q63597944 | A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week |
| Q66070254 | A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes |
| Q113943507 | A Research Study of How NNC0174-0833 Behaves in Chinese Volunteers Who Are Normal Weight, Overweight or With Obesity |
| Q63591761 | A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity |
| Q61907707 | A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese |
| Q66062031 | A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese |
| Q66066859 | A Research Study of How Overdosing of a New Once Weekly Medicine NNC0148-0287 C (Insulin 287) Influences the Blood Sugar Level in People With Type 2 Diabetes |
| Q63597941 | A Research Study of How a New Medicine NNC0148-0287 C (Insulin 287) Works in the Body of People With Kidney Problems |
| Q63396960 | A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese |
| Q62042588 | A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese |
| Q66064540 | A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage |
| Q113923893 | A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors |
| Q63595305 | A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes. |
| Q64150398 | A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes |
| Q66064333 | A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes |
| Q66062674 | A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity |
| Q113898779 | A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3) |
| Q100789098 | A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before |
| Q113898466 | A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin |
| Q64150023 | A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before |
| Q113892800 | A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes |
| Q113893693 | A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes |
| Q113911796 | A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) |
| Q66068356 | A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study |
| Q113926550 | A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial) |
| Q113919592 | A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity |
| Q113897186 | A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes |
| Q63595166 | A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together |
| Q64139917 | A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity |
| Q64150350 | A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes |
| Q61907879 | A Research Study to Look at Similarity Between Semaglutide Versions in Different Injection Tools |
| Q64150334 | A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease |
| Q113923864 | A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (C |
| Q64792199 | A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria |
| Q113922998 | A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in China as Part of Local Clinical Practice |
| Q63592079 | A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia |
| Q64173199 | A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates |
| Q64222039 | A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden |
| Q64673261 | A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone |
| Q64673661 | A Single Dose Trial in Healthy Caucasians and Japanese Subjects Investigating the Pharmacokinetics of Somatropin |
| Q63333822 | A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A |
| Q63340483 | A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 |
| Q66063499 | A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity |
| Q113892765 | A Study Following Males With Haemophilia A on Prophylaxis With Esperoct® |
| Q63595743 | A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN |
| Q63575567 | A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) |
| Q113896879 | A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea |
| Q105088297 | A Study Investigating the Distribution and Metabolism of Three 14C-labeled Radioactive Study Compounds |
| Q113943722 | A Study Investigating the Safety and Performance of DV3395, a New Concept Device for the Delivery of Medicine. |
| Q65385830 | A Study Looking Into the Effect of NNC 55-0414 in Subjects With Type 2 Diabetes |
| Q113911455 | A Study Looking at How Insulin Icodec is Taken up in the Blood When Administered in Different Injection Sites in People With Type 2 Diabetes |
| Q63592129 | A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal |
| Q65465343 | A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan |
| Q63571544 | A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia |
| Q66033447 | A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump |
| Q64123767 | A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver |
| Q65348026 | A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients |
| Q63587923 | A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects |
| Q65363745 | A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan |
| Q113943233 | A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump |
| Q104675229 | A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus |
| Q66066123 | A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes |
| Q113893204 | A Study to Look at the Safety of NNC0363-0845 in Healthy People and People With Type 1 Diabetes |
| Q113910264 | A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People From China With Type 2 Diabetes |
| Q113895903 | A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease |
| Q64647960 | A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin |
| Q64647959 | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Children With Type 1 Diabetes |
| Q64694110 | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh |
| Q63334365 | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India |
| Q64680287 | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Malaysia |
| Q64694730 | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Singapore |
| Q64678543 | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Taiwan |
| Q64697607 | A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand |
| Q64223178 | A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects |
| Q64353360 | A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events |
| Q65365070 | A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes |
| Q64646078 | A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes |
| Q64173381 | A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral A |
| Q64140028 | A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs) |
| Q64219916 | A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of F |
| Q63829606 | A Trial Comparing the Effect of NN1250 After Different Routes of Injection in Healthy Subjects |
| Q66073335 | A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs |
| Q64353968 | A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus |
| Q64649946 | A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes |
| Q65341070 | A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus. |
| Q63316791 | A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin |
| Q65364582 | A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Wit |
| Q63403863 | A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes |
| Q64220756 | A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects |
| Q64397660 | A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes |
| Q65359470 | A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes |
| Q64601840 | A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes |
| Q61969378 | A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes |
| Q64150782 | A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors |
| Q64654871 | A Trial Evaluating the Blood Glucose-lowering Effect of NN1250 in Subjects With Type 2 Diabetes |
| Q63832079 | A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes |
| Q64150785 | A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors |
| Q63830065 | A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes |
| Q61975136 | A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency |
| Q66079575 | A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects |
| Q65394385 | A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Q63837293 | A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes |
| Q64635392 | A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes |
| Q63833872 | A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes |
| Q64663236 | A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes |
| Q66075792 | A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects |
| Q64804588 | A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects |
| Q65356378 | A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes |
| Q65352716 | A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes |
| Q65362878 | A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes |
| Q63317755 | A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus |
| Q65367663 | A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Typ |
| Q65359532 | A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Ora |
| Q63830457 | A Trial Investigating the Exposure of NN5401 in Young Adults and Elderly Subjects With Type 1 Diabetes |
| Q64222711 | A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects |
| Q65536143 | A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function |
| Q64644829 | A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes |
| Q63843971 | A Trial Investigating the Pharmacodynamic Properties of NN5401 in Subjects With Type 1 Diabetes |
| Q64349146 | A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes |
| Q64663121 | A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function |
| Q64397529 | A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes |
| Q64613266 | A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes |
| Q61969931 | A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes |
| Q64351716 | A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes |
| Q66080517 | A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus |
| Q113911454 | A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Insulin Icodec in Subjects With Type 2 Diabetes |
| Q64677140 | A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects |
| Q64639447 | A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency |
| Q66079312 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes |
| Q64626369 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects |
| Q64604390 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus |
| Q65356233 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes |
| Q63833269 | A Trial Investigating the Total Exposure of NN5401 (Insulin Degludec/Insulin Aspart) in Children, Adolescents and Adult Subjects With Type 1 Diabetes |
| Q64663688 | A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes |
| Q65372699 | A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics |
| Q65372692 | A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate |
| Q65393189 | A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years |
| Q64662353 | A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics |
| Q64662819 | A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese Volunteers |
| Q65356533 | A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects |
| Q64817299 | A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects |
| Q61906801 | A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector) |
| Q64398109 | A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency |
| Q64216877 | A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles |
| Q65370161 | A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes |
| Q64817060 | A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects |
| Q63838256 | A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes |
| Q64658820 | A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers |
| Q63834743 | A Two Part Trial Investigating the Safety of NN9924 in Healthy Male Subjects |
| Q65376590 | A Two Part Trial Investigating the Safety of NN9925 in Healthy Male Subjects |
| Q63316142 | Activated Recombinant Human Factor VII Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease |
| Q63843907 | Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever |
| Q63843931 | Activated Recombinant Human Factor VII in Pelvic-acetabular Fracture Reconstruction |
| Q62054174 | Adverse Event Data Collection From External Registries on Nonacog Beta Pegol |
| Q104676030 | Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol |
| Q113945004 | An International Chart Review and Survey for the Prevalence and Clinical Management of Atherosclerotic Cardiovascular Diseases in Patients With Type 2 Diabetes Across Countries in the Middle East and Africa |
| Q63572327 | An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry |
| Q63574965 | An International Survey of the Occurrence of Cardiovascular Disease Among Patients With Type 2 Diabetes |
| Q64139935 | An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes |
| Q64640207 | An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes |
| Q64660106 | An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone) |
| Q63318292 | An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical Practice |
| Q63318535 | An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus |
| Q64693730 | An Observational Study in Type 2 Diabetic Patients on Oral Antidiabetic Drugs and Basal Insulin in Near East Countries |
| Q64043338 | An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment |
| Q64043594 | An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment |
| Q64042858 | An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects |
| Q64709994 | An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes |
| Q64351596 | Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD) |
| Q64794866 | Awareness, Care & Treatment In Obesity Management - An International Observation |
| Q113945170 | Awareness, Care & Treatment In Obesity Management - An Observation in Asia Pacific |
| Q113923067 | Awareness, Care & Treatment In Obesity Management - An Observation in Switzerland |
| Q66069273 | Awareness, Care & Treatment in Obesity Management (ACTION) Study |
| Q63011560 | Awareness, Care and Treatment in Obesity Management |
| Q63404339 | Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE) |
| Q64723713 | Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes |
| Q63316407 | Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects |
| Q63318132 | Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese Subjects |
| Q63318164 | Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male Subjects |
| Q63318128 | Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Subjects |
| Q64644666 | Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects |
| Q63318159 | Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male Subjects |
| Q63318123 | Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Subjects |
| Q63317223 | Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL) |
| Q61956803 | Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes |
| Q63807273 | Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers |
| Q64724002 | Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy |
| Q66024894 | Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations |
| Q64639737 | Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women |
| Q64647849 | Changing Diabetes® World Tour |
| Q97047147 | Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern |
| Q64723302 | Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients |
| Q64646675 | Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 Diabetes |
| Q65316022 | Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin |
| Q63844163 | Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients |
| Q63578834 | Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus |
| Q65376426 | Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus |
| Q61980469 | Comparison of 2 NovoFine® Needles on the Reflux of Insulin |
| Q65385490 | Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin |
| Q63320275 | Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes |
| Q63320271 | Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects |
| Q63320765 | Comparison of Biphasic Insulin Aspart 30 Individually Adjusted by the Subject and the Trial Physician, Both Combined With Metformin in Subjects With Type 2 Diabetes |
| Q65471335 | Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes |
| Q66059263 | Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes |
| Q66031232 | Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes |
| Q66024912 | Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes |
| Q65379099 | Comparison of Biphasic Insulin Aspart Produced by the NN2000 Process to Current Process to in Type 2 Diabetes |
| Q65473271 | Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes |
| Q65473261 | Comparison of Efficacy and Safety of Insulin Detemir and NPH Insulin in Children and Adolescents With Type 1 Diabetes |
| Q64709172 | Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes |
| Q65378681 | Comparison of Glycemic Control Achieved With 2 Different Needles |
| Q61967821 | Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Healthy Volunteers |
| Q65470005 | Comparison of Human Insulin Produced by the Current Process and the NN729 Process in Type 1 Diabetes |
| Q65470366 | Comparison of Human Insulin to Insulin Inhalation Solution in Children With Type 1 Diabetes |
| Q64660909 | Comparison of Hypoglycaemic Response Between NN1250 and Insulin Glargine in Type 1 Diabetics |
| Q64646684 | Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process |
| Q64644664 | Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese |
| Q64725315 | Comparison of Insulin Aspart Produced by the NN2000 Process to the Current Process in Type 1 Diabetes |
| Q66033118 | Comparison of Insulin Detemir Given Once or Twice Daily in Type 1 Diabetes |
| Q62105896 | Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes |
| Q66031265 | Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes |
| Q64646679 | Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 Diabetes |
| Q62105710 | Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes |
| Q66024904 | Comparison of Insulin Detemir With NPH Insulin in Type 1 Diabetes |
| Q66024907 | Comparison of Insulin Detemir and Insulin Semilente®MC in Type 1 Diabetes |
| Q64715079 | Comparison of Insulin Detemir and NPH With Respect to Lowering the Blood Sugar and Symptoms Experienced by Type 1 Diabetics During Hypoglycaemia |
| Q65538070 | Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes |
| Q66024910 | Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes |
| Q66024909 | Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes |
| Q66024908 | Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes. |
| Q63317740 | Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers |
| Q64710659 | Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance |
| Q61956320 | Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes |
| Q61956609 | Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes |
| Q61938368 | Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes |
| Q65377454 | Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes |
| Q64693911 | Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes |
| Q64657359 | Comparison of NN1250 Versus Insulin Glargine in Subjects With Type 2 Diabetes |
| Q64699037 | Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes |
| Q61938110 | Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes |
| Q65535671 | Comparison of NN1250 With Insulin Glargine in Type 1 Diabetes |
| Q65536126 | Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes |
| Q64658519 | Comparison of NN1250 With Sitagliptin in Subjects With Type 2 Diabetes Never Treated With Insulin |
| Q64662784 | Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes |
| Q64693706 | Comparison of NN5401 Versus Biphasic Insulin Aspart 30 on a Twice Daily Regimen in Subjects With Type 2 Diabetes Mellitus |
| Q64683677 | Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes |
| Q64666519 | Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q63815684 | Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes |
| Q64683700 | Comparison of NN5401 With Insulin Glargine, Both in Combination With Oral Antidiabetic Drugs, in Subjects With Type 2 Diabetes |
| Q65383623 | Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes |
| Q65389241 | Comparison of NovoFine® Needles (4 mm vs. 6 mm) |
| Q64694449 | Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes |
| Q64723977 | Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 50 to Biphasic Insulin Aspart 70 in Type 2 Diabetes |
| Q65373574 | Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes |
| Q65541226 | Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes |
| Q64647140 | Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes |
| Q64644825 | Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes |
| Q63317382 | Comparison of Three Liraglutide Formulations in Healthy Volunteers |
| Q64646550 | Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers |
| Q63320297 | Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 Diabetes |
| Q63319684 | Comparison of Two Formulations of Biphasic Insulin Aspart 70 |
| Q64639736 | Comparison of Two Insulin Aspart Formulations in Healthy Volunteers |
| Q63334161 | Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus |
| Q61956501 | Comparison of Two Liraglutide Formulations in Healthy Volunteers |
| Q64724074 | Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes |
| Q64724104 | Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes |
| Q61938113 | Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes |
| Q64723766 | Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes |
| Q64723752 | Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes |
| Q65469866 | Comparison of Two Pen Systems in Patients With Diabetes Treated With Insulin |
| Q64655888 | Comparison of a Blood Clotting Drug (Recombinant Factor XIII) Produced by Two Different Manufacturers in Healthy Male Subjects |
| Q64694523 | Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects |
| Q64695267 | Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs |
| Q65380835 | Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes |
| Q63829366 | Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment |
| Q61956785 | Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers |
| Q65371083 | Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine |
| Q64660980 | Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin |
| Q64672389 | Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 Diabetes |
| Q64046596 | Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes |
| Q65540866 | Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures |
| Q61956820 | Diabetes Attitudes Wishes and Needs |
| Q66045287 | Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects |
| Q62105874 | Dose Response to Recombinant Factor VIIa When Administered for Bleed |
| Q64718666 | Dose Study in Growth Hormone Deficient Adults Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 |
| Q64717238 | Dose Study in Healthy Japanese Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 |
| Q63835894 | Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx® |
| Q65356030 | Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects |
| Q65346844 | Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes |
| Q64140056 | Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes |
| Q63336026 | Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes |
| Q66079336 | Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting |
| Q66079339 | Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin |
| Q65538596 | Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Q65538280 | Effect of Biphasic Insulin Compared to Biphasic Insulin Combined With Insulin Aspart, With or Without Metformin in Type 2 Diabetes |
| Q64710039 | Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes |
| Q61939015 | Effect of Different Insulin Administrations, All in Combination With Metformin, on Glycaemic Control in Subjects With Type 2 Diabetes Inadequately Controlled by Oral Anti-diabetic Drugs |
| Q61922046 | Effect of Exercise on the Absorption of Inhaled Human Insulin in Subjects With Type 1 Diabetes |
| Q63580527 | Effect of Fiasp® in Type 1 Diabetes Treatment |
| Q65539330 | Effect of Growth Hormone in Children With Growth Hormone Deficiency |
| Q66024903 | Effect of Growth Hormone on Bone Mineral Density in Young Adults With Child-hood Onset Growth Hormone Deficiency |
| Q65385189 | Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes |
| Q61921376 | Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes |
| Q64675464 | Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Q61979324 | Effect of Insulin Detemir on Use of Energy in Type 1 Diabetes |
| Q61938167 | Effect of Kettlebell Training on Musculoskeletal and Cardiovascular Health |
| Q61955995 | Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes |
| Q61956067 | Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes |
| Q65336528 | Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome |
| Q66080119 | Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity |
| Q65386169 | Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Q63317911 | Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea |
| Q64645612 | Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 Diabetes |
| Q66027835 | Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes |
| Q65386327 | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Q63815679 | Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes |
| Q63815677 | Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes |
| Q64647419 | Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH |
| Q61956322 | Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes |
| Q61956497 | Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes |
| Q64645838 | Effect of Liraglutide on Heart Frequency in Healthy Volunteers |
| Q61956787 | Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes |
| Q61956495 | Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes |
| Q61956065 | Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group |
| Q65382932 | Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Q64723741 | Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes |
| Q64657392 | Effect of NN5401 in Japanese Subjects With Type 1 Diabetes |
| Q65376674 | Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes |
| Q64695111 | Effect of Renal Impairment on the Pharmacokinetics of NN9535 |
| Q65385873 | Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes |
| Q63843113 | Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes |
| Q63316102 | Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients |
| Q61915470 | Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily |
| Q64723510 | Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin Cancer |
| Q66024913 | Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes |
| Q65391548 | Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. |
| Q65389761 | Efficacy Study of IL-21 to Treat Metastatic Melanoma |
| Q65382207 | Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer |
| Q63316425 | Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic Cystitis |
| Q63315993 | Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients |
| Q63316231 | Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation |
| Q63315828 | Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation |
| Q63832998 | Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen |
| Q64723755 | Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen® in Insulin Naive Subjects With Type 2 Diabetes |
| Q64639897 | Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes |
| Q64722361 | Efficacy and Safety of Biphasic Insulin Aspart 30 With Metformin in Type 2 Diabetes |
| Q64723009 | Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes |
| Q64725234 | Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes |
| Q64723224 | Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes |
| Q61956199 | Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes |
| Q65368444 | Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes |
| Q64625261 | Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes |
| Q65364836 | Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes |
| Q65342640 | Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes |
| Q64183704 | Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes |
| Q65380284 | Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age |
| Q65471207 | Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes |
| Q65388392 | Efficacy and Safety of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes |
| Q65378698 | Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes |
| Q64724933 | Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes |
| Q61934386 | Efficacy and Safety of Insulin Aspart vs. Human Insulin During Pregnancy by Women With Type 1 Diabetes |
| Q63333825 | Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens |
| Q65383113 | Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes |
| Q64725249 | Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q64724597 | Efficacy and Safety of Insulin Detemir in Type 1 Diabetes |
| Q64725383 | Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone |
| Q63316440 | Efficacy and Safety of Levemir® Used as Basal Insulin |
| Q61975137 | Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes |
| Q64644656 | Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment |
| Q63316257 | Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes |
| Q63318970 | Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes |
| Q64652480 | Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation |
| Q64724984 | Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q61956062 | Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent |
| Q64649411 | Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B |
| Q61956189 | Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes |
| Q63807829 | Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. |
| Q66081893 | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only |
| Q66074956 | Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin |
| Q63316144 | Efficacy and Safety of Repaglinide Combined With Insulin NPH in Subjects With Type 2 Diabetes |
| Q65373548 | Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes |
| Q65470108 | Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes |
| Q65470306 | Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes |
| Q61894510 | Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes |
| Q65361931 | Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes |
| Q64598494 | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes |
| Q66072169 | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus |
| Q64336466 | Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes |
| Q65360587 | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes |
| Q64140051 | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) |
| Q66043695 | Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes |
| Q64622566 | Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin |
| Q65390577 | Efficacy and Safety of Three Times a Day BIAsp-70 Compared to Two Times a Day BIAsp-30 in Subjects With Type 2 Diabetes |
| Q64725360 | Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes |
| Q63807858 | Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes |
| Q63316281 | Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding |
| Q64709786 | Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs |
| Q65375351 | Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis |
| Q62105423 | Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia |
| Q66024897 | Efficacy on Height in SGA Children Treated With Growth Hormone |
| Q64715402 | Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics |
| Q65384268 | Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis |
| Q105088726 | Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Ozempic® (Semaglutide s.c.) in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data |
| Q61957397 | Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries |
| Q63315932 | Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency |
| Q64646353 | Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. |
| Q66080071 | Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A |
| Q63807106 | Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes |
| Q65470001 | Evaluating the Use of Two Different Needles in Subjects With Diabetes |
| Q65362387 | Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period |
| Q64719892 | Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes |
| Q64719104 | Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency |
| Q63571654 | Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial |
| Q64647548 | Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A |
| Q64645840 | Evaluation of Safety and Parameters of Application Technique |
| Q66069559 | Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes. |
| Q64680979 | Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir |
| Q65377265 | Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes |
| Q65541056 | Factor VIIa in Acute Intracerebral Haemorrhage |
| Q63817302 | First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects |
| Q63317376 | First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects |
| Q63840939 | First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis |
| Q61904787 | First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men. |
| Q64802891 | First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People. |
| Q64652028 | First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis |
| Q64644540 | French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin |
| Q63315550 | French National Registry of Children Born Small for Gestational Age Treated With Somatropin |
| Q64643960 | French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients |
| Q113941591 | French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome |
| Q64646552 | Frequency of Episodes of Hypoglycaemia During Treatment With Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q64639919 | Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes |
| Q64354082 | GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus |
| Q64354083 | GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus |
| Q113909767 | GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan. |
| Q64719531 | Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins |
| Q64647134 | Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 Diabetes |
| Q64639931 | Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q65382822 | Growth Hormone Deficiency in Adults (GHDA) |
| Q66024906 | Growth Hormone Treatment in Adult Patients With Chronic Kidney Disease |
| Q66024900 | Growth Hormone Treatment in Children Born Small for Gestational Age (SGA) |
| Q66024896 | Growth Hormone Treatment in Infants Aged 1 to 2 Years With Chronic Renal Insufficiency (CRI) and Growth Retardation. |
| Q66024901 | Growth Hormone Treatment of Children Born With Retarded Intrauterine Growth at Age 2-5 Years |
| Q64639928 | Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation |
| Q65372535 | Growth Response in Girls With Turner Syndrome |
| Q61918440 | Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds |
| Q65378748 | High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors |
| Q64724299 | Human Insulin NPH and Insulin Aspart in Type 1 Diabetes |
| Q63340999 | Impact of Dietary Intervention on Weight Change in Subjects With Type 2 Diabetes |
| Q64351872 | Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia |
| Q64646625 | Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy |
| Q62811708 | In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database |
| Q66078763 | In-market Utilisation of Liraglutide Used for Weight Management in Europe |
| Q66031707 | Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury |
| Q66064924 | Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA) |
| Q64350206 | Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects |
| Q61956510 | Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal Women |
| Q64726088 | Initiation of Insulin Aspart in Type 2 Diabetes |
| Q113888989 | Injection Site Pain Comparison of Excipient Solutions |
| Q66034370 | Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population |
| Q63319779 | Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy Volunteers |
| Q64607077 | Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects |
| Q61862228 | Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency |
| Q63578333 | Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus |
| Q64602483 | Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects |
| Q64602476 | Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects |
| Q64602000 | Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects |
| Q64621236 | Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome |
| Q65375315 | Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects |
| Q65352883 | Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function |
| Q64392503 | Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus |
| Q63813179 | Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. |
| Q63316254 | Investigation of Optimal Dosing Conditions for a Long Acting GLP-1 Analogue in Healthy Male Subjects |
| Q66070731 | Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function. |
| Q66041624 | Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function |
| Q65348022 | Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus |
| Q66046753 | Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity |
| Q64645504 | Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects |
| Q64640761 | Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A |
| Q64661171 | Investigation of the Response Relationship of NN5401 in Type 1 Diabetics |
| Q64599145 | Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects |
| Q64641341 | Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes |
| Q64641065 | Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects |
| Q66079291 | LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors. |
| Q65470469 | Liquid Somatropin Formulation in Children With Growth Hormone Deficiency |
| Q63829261 | Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results |
| Q64647082 | Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2 |
| Q61980568 | Localisation of Potential Insulin Deposits in Normal Weight and Obese Diabetics Using 6 mm and 12 mm Long Needles |
| Q64139944 | Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial |
| Q64637161 | Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation |
| Q64710149 | Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects |
| Q64716831 | Long Term Safety Trial to Compare Insulin Treatment With Preprandial Inhaled Human Insulin to s.c. Insulin Aspart Both Combined With NPH in Subjects With Type 1 Diabetes |
| Q63318168 | Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes |
| Q61956142 | Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q64648922 | Long Term Safety of Biphasic Insulin Aspart 30 in Juveniles With Type 1 Diabetes |
| Q64601702 | Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice |
| Q66024898 | Long-term Trial on Growth Hormone Deficiency in Adults (GHDA) |
| Q64645609 | Metabolism and Excretion of Liraglutide in Healthy Male Volunteers |
| Q64677691 | Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery |
| Q64621975 | Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes |
| Q63844467 | Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors |
| Q64644630 | Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice |
| Q64644628 | Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery |
| Q63336275 | Non-Interventional Study on Safety of Liraglutide in Subjects With Type 2 Diabetes |
| Q63815926 | Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents |
| Q63320276 | NovoLet® Acceptance Study Within the Hospital Practise in Indonesia |
| Q63320291 | NovoLet® Surveillance Study on Using Human Insulin System in Indonesia |
| Q66031592 | NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes |
| Q66032351 | Novofine Autocover Safety Needle Versus BD Safety Glide |
| Q64040831 | Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX |
| Q64695625 | Observational Prospective Study on Patients Treated With Norditropin® |
| Q64042208 | Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors |
| Q64041136 | Observational Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 2 Diabetes Mellitus |
| Q63316443 | Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment |
| Q64042800 | Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control |
| Q64714898 | Observational Study Evaluating the Safety of NovoMix® in Type 2 Diabetes Patients Previously Treated With a Human Premix Insulin |
| Q63320050 | Observational Study With InnoLet® in Daily Clinical Practice |
| Q63320272 | Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction |
| Q61981061 | Observational Study in Type 2 Diabetics Failing on Oral Antidiabetic Therapy and Starting on Insulin Treatment |
| Q64697531 | Observational Study in Type 2 Diabetics Treated by an Intensive Insulin Treatment of Levemir® |
| Q63320298 | Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes |
| Q64045537 | Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus |
| Q61957714 | Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™ |
| Q64715901 | Observational Study of NovoMix® 50 for Treatment of Type 2 Diabetics for 12 Months |
| Q63318287 | Observational Study of NovoNorm® in Subjects With Diabetes |
| Q63828959 | Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes |
| Q64697534 | Observational Study of NovoPen® 4 on Treatment Satisfaction of Insulin Therapy in Type 1 or Type 2 Subjects With Diabetes Mellitus |
| Q64718744 | Observational Study of Patients Using Levemir® or Insulatard® as Start Insulin for Treatment of Diabetes |
| Q64043363 | Observational Study of Patients Using NovoRapid® or Soluble Human Insulin for Treatment of Type 2 Diabetes |
| Q64721005 | Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes |
| Q64646690 | Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes |
| Q64707711 | Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues |
| Q64721199 | Observational Study of Type 2 Diabetes Patients Failing on Oral Anti-diabetic Agents Initiated on Levemir® or Insulatard® |
| Q63318511 | Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and Hypos |
| Q63833036 | Observational Study of the Safety and Efficacy of Norditropin® in Patients With SGA (Small for Gestational Age) Short Stature That Are Still Growing |
| Q64046609 | Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin |
| Q63814334 | Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes |
| Q63063159 | Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes |
| Q63816811 | Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes |
| Q63320287 | Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice |
| Q64695021 | Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients |
| Q63062804 | Observational Study on Safety of Self-titration of Once Daily Levemir® |
| Q64719923 | Observational Study on Treatment Satisfaction of Levemir® Versus Protaphane® During "Real-life" Usage in Germany |
| Q61980684 | Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication |
| Q64043525 | Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany |
| Q64043499 | Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics |
| Q64046903 | Observational Study to Assess the Efficacy and Safety of NovoRapid™ Flexpen™ |
| Q64043771 | Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes |
| Q64718651 | Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents |
| Q64042834 | Observational Study to Evaluate Safety of Levemir® in Type 1 and Type 2 Diabetes |
| Q64718671 | Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes |
| Q64715668 | Observational Study to Evaluate the Effectiveness and Safety of Levemir®, NovoMix® 30 and NovoRapid® in Insulin naïve Subjects With Type 2 Diabetes |
| Q64043160 | Observational Study to Evaluate the Efficacy and Safety of NovoMix® 30 in Type 1 and 2 Diabetes |
| Q64041792 | Observational Study to Evaluate the Safety of Levemir® in Diabetes |
| Q63317212 | Observational Study to Evaluate the Safety of Levemir® in Patients With Diabetes |
| Q64694322 | Observational Study to Evaluate the Safety of Levemir® in Type 2 Diabetes |
| Q64697528 | Observational Study to Investigate the Efficacy and Safety of Human Insulin or Insulin Analogue Treatments in Type 2 Diabetes Subjects |
| Q64042080 | Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 Diabetes |
| Q64717992 | Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes |
| Q64707469 | PROPACT: Retrospective Prophylaxis Patient Case Collection |
| Q64646276 | Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes |
| Q65331419 | Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial |
| Q64646673 | Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis |
| Q63841131 | Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes |
| Q64694376 | Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 in Type 2 Diabetes |
| Q64639372 | Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers |
| Q63319132 | Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes |
| Q63841164 | Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers |
| Q63318279 | Pharmacokinetics of Insulin Detemir in Healthy Chinese Male Subjects |
| Q64646272 | Pharmacokinetics of Insulin Detemir in Healthy Volunteers From Taiwan |
| Q63318525 | Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes |
| Q64646270 | Pharmacokinetics of Insulin Detemir in Subjects With Type 2 Diabetes |
| Q63316140 | Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State |
| Q61957525 | Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic Haemodialysis |
| Q64639934 | Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes |
| Q64350636 | Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment |
| Q64350850 | Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function |
| Q63320286 | Physiological Concept of Insulin Therapy in Subjects With Type 2 Diabetes |
| Q64607244 | Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India |
| Q63613295 | Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome) |
| Q113926592 | Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya® |
| Q113887567 | Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic® |
| Q64679807 | Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database |
| Q64352203 | Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba® |
| Q65353793 | Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®) |
| Q63587218 | Post-marketing Surveillance (Use Result Surveillance) With Refixia® |
| Q63316287 | Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography |
| Q63839806 | Preference Study Between NovoFine® Autocover™ and a NovoFine® 8 mm Needle |
| Q65379701 | Preventive Effect of Treatment With Estradiol Vaginal Tablets on Recurrent Urinary Tract Infections in Post-menopausal Women |
| Q64643817 | Psychosocial Factors Related to Compliance With Treatment With Biphasic Insulin Analogues |
| Q64150380 | RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan |
| Q63591845 | Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity |
| Q61921406 | Recombinant Factor VIIa in Acute Intracerebral Haemorrhage |
| Q66059078 | Reliability of Dosing With NovoLog® Mix 70/30 FlexPen® Compared With Vial and Syringe |
| Q62063087 | Research Study Comparing Different Tablets With the Study Medicine Semaglutide in Healthy Men |
| Q64139973 | Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes |
| Q64140009 | Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes |
| Q66068026 | Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. |
| Q66066676 | Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity |
| Q66066660 | Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity |
| Q63572406 | Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity |
| Q113920946 | Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis |
| Q62062271 | Research Study of a New Medicine (NNC9204-1706) in People With Overweight or Obesity |
| Q113914124 | Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) |
| Q113919226 | Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes |
| Q105493458 | Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes |
| Q113920647 | Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1) |
| Q113915455 | Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity |
| Q64794504 | Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes |
| Q113939399 | Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes |
| Q61906777 | Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program |
| Q63572056 | Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period |
| Q64150971 | Retrospective Cohort Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine |
| Q113921273 | SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity |
| Q64796434 | STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity |
| Q63583312 | STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity |
| Q64722521 | Safety Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689 |
| Q64664855 | Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors |
| Q63316104 | Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy |
| Q63316415 | Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery |
| Q63316004 | Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation |
| Q63839012 | Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes |
| Q65390022 | Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes |
| Q65390622 | Safety and Efficacy of Inhaled Insulin in Type 2 Diabetes |
| Q65389145 | Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes |
| Q61956228 | Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes |
| Q64639377 | Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes |
| Q66035493 | Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes |
| Q66031685 | Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes |
| Q64725353 | Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 Diabetes |
| Q64725046 | Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes |
| Q61955922 | Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone |
| Q64649449 | Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773 |
| Q64651057 | Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients |
| Q65357407 | Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B |
| Q66031269 | Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents |
| Q61957526 | Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency |
| Q65377332 | Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 |
| Q64140234 | Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A |
| Q64173567 | Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A |
| Q64694074 | Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects |
| Q63319853 | Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A |
| Q63833265 | Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A |
| Q64654525 | Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A |
| Q65365331 | Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers |
| Q66037058 | Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency |
| Q63316006 | Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage |
| Q65374355 | Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage |
| Q66031871 | Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury |
| Q64695549 | Safety and Tolerability of Anti-IL-20 in Healthy Volunteers and Patients With Rheumatoid Arthritis |
| Q63834382 | Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis |
| Q63316002 | Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers |
| Q63316950 | Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers |
| Q64644658 | Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers |
| Q61956794 | Safety and Tolerability of Liraglutide in Healthy Male Volunteers |
| Q61956791 | Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes |
| Q63842821 | Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes |
| Q61956519 | Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function |
| Q65377414 | Safety and Tolerability of NN9068 in Healthy Male Volunteers |
| Q63318829 | Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis |
| Q64664409 | Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B |
| Q65383274 | Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD) |
| Q65382266 | Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma |
| Q64725231 | Safety of Insulin Detemir in Children With Type 1 Diabetes |
| Q64665590 | Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes |
| Q64662821 | Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 |
| Q63336638 | Safety of NNC 0123-0000-0338 in Healthy Subjects |
| Q63816539 | Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B |
| Q64647435 | Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome |
| Q64645206 | Safety of Treatment Initiation With Biphasic Insulin Aspart 30 in Hospitalised Patients With Type 2 Diabetes |
| Q63816299 | Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency |
| Q64606975 | Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass |
| Q61956183 | Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. |
| Q64719942 | Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers |
| Q61955307 | Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects |
| Q64644662 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers |
| Q63396959 | Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Q63320767 | Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers |
| Q63321017 | Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy Volunteers |
| Q62106175 | Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children |
| Q64672688 | Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome |
| Q64645842 | Special Survey for Long Term Application |
| Q66042645 | Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients |
| Q63400834 | Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device |
| Q63320908 | Surveillance Study of NovoRapid® for New Drug Re-examination |
| Q63335829 | Survey Evaluating the Psychosocial Effects of Living With Haemophilia |
| Q63320290 | Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands |
| Q63838253 | The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification |
| Q64679192 | The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes |
| Q63320278 | The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes |
| Q64042823 | The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus |
| Q63842299 | The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes |
| Q61921812 | The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes |
| Q64722896 | The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus |
| Q64683760 | The Effect of NN1250 in Subjects With Type 2 Diabetes of Different Race and/or Ethnic Origin |
| Q61980143 | The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis |
| Q64220069 | The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes |
| Q64351293 | The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes |
| Q64644833 | The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy |
| Q64642921 | The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy |
| Q65390634 | To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together |
| Q63319943 | To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1 |
| Q65538355 | To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c |
| Q64714844 | To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo |
| Q63320651 | Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin |
| Q65370227 | Treatment of Congenital Factor VII Deficiency |
| Q65345698 | Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects |
| Q64335619 | Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects |
| Q64221891 | Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo |
| Q62105420 | Trial of NovoSeven® in Haemophilia - Joint Bleeds |
| Q65346370 | Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy |
| Q64603917 | Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. |
| Q64638542 | Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes |
| Q113894886 | Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. |
| Q102153444 | Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities |
| Q63599506 | Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity |
| Q62106465 | Use of Activated Recombinant FVII in Spinal Surgery |
| Q66027833 | Use of Activated Recombinant Human Factor VII in Cardiac Surgery |
| Q63316284 | Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment |
| Q66027820 | Use of NovoSeven® in Active Variceal Bleeding |
| Q64647439 | Use of Somatropin in Turner Syndrome |
| Q64123537 | Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study |
| Q62105416 | Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms |
| Q61956755 | Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen Deficiency |
| Q65316225 | Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD) |
| Q63598104 | Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy |
| Q64646274 | Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 Diabetes |
| Q64646280 | Within-subject Variability of Insulin Detemir in Healthy Volunteers |
| Q113924065 | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation |
